News & Videos - FIVE PRIME THERAPEUTICS INC.

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics PR Newswire THOUSAND OAKS, Calif., April 16, 2021 THOUSAND OAKS, Calif. , April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Five Prime Therapeutics (NasdaqGS: FPRX) to Amgen (NasdaqGS: AMGN). Under the terms of the proposed transaction, shareholders of Five Prime will receive only $38.00 in cash for each share of Five Prime that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Five Prime Therapeutics, Inc. - FPRX PR Newswire NEW YORK, March 5, 2021 NEW YORK , March 5, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Five Prime Therapeutics, Inc. ("FPRX" or...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Five Prime Therapeutics, Inc. PR Newswire NEW YORK, March 4, 2021 NEW YORK , March 4, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Five Prime Therapeutics, Inc. ("Five Prime" or the "Company") (NASDAQ: FPRX) in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN). The transaction is structured as an all-cash tender offer...

Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen PR Newswire MILWAUKEE, March 4, 2021 MILWAUKEE , March 4, 2021 /PRNewswire/ -- Ademi LLP is investigating Five Prime (NASDAQ: FPRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen. Click here to learn how to join the action: http://ademilaw.com/case/five-prime-therapeutics or call Guri Ademi toll-free at 866-264-3995....

Should you invest in Nio, Rocket Companies, Carnival Corp, Five Prime Therapeutics, or Burlington Stores? PR Newswire NEW YORK, March 4, 2021 NEW YORK , March 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, RKT, CCL, FPRX, and BURL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of...

Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime’s innovative pipeline to Amgen’s leading oncology portfolio. Five Prime’s lead asset, bemarituzumab, is a...

Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen's Innovative Oncology Portfolio Amgen to Host Investor Call at 10:30 a.m. EST PR Newswire THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , March 4, 2021...

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday, March 10, 2021 after the U.S. financial markets close. Five Prime will also host a conference call and live audio webcast that same day at 4:30 p.m. (ET) / 1:30 p.m. (PT) to provide a general business update and discuss the company’s financial results. The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors"...

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the Cowen 41 st Annual Health Care Conference on Thursday, March 4, 2021 at 10:30 a.m. ET / 7:30 a.m. PT. Live audio webcast of the presentation will be accessible and available for replay from the “Events & Presentations” section of the Company’s...

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the virtual SVB Leerink 10 th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 10:00 a.m. ET / 7:00 a.m. PT. Live audio webcast of the presentation will be accessible and available for replay from the “Events & Presentations”...

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer, are scheduled to participate in a fireside chat at the virtual Guggenheim Healthcare Talks: Oncology Day on Friday, February 12, 2021 at 1:00 p.m. ET/10:00 a.m. PT. Live audio webcast of the fireside chat will be accessible and available for replay from the “Events & Presentations” section of the...

Thinking about buying stock in Zomedica, Zosano Pharma, TapImmune, Five Prime Therapeutics, or Inuvo? PR Newswire NEW YORK, Jan. 5, 2021 NEW YORK , Jan. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, ZSAN, MRKR, FPRX, and INUV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ZOM:...

...

...

...

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced results for the third quarter of 2020 in addition to providing an update on the company’s recent activities. “We look forward to achieving three milestones before the end of the year that will inform future development of our pipeline,” said Tom Civik, Chief Executive Officer of Five Prime Therapeutics....

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2020 operational and financial results on Tuesday, November 3, 2020 after the U.S. financial markets close. Five Prime will also host a conference call and live audio webcast on Tuesday, November 3, 2020 at 4:30 p.m. (ET) / 1:30 p.m. (PT) to provide a general business update and discuss the...

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that Tom Civik, Chief Executive Officer of Five Prime Therapeutics, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therapeutics, will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference on Thursday, September 10 th at 9:00am Pacific...

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced results for the second quarter of 2020 in addition to providing an update on the company’s recent activities. “We remain on track to generate data from the FIGHT Phase 2 trial by year-end or early next year and have monotherapy safety and efficacy data for FPT155 in-house by year-end,” said Tom Civik,...